World Conference on Lung Cancer 2022: Updates in NSCLC

home / post-conference-perspectives / world-conference-on-lung-cancer-2022-updates-in-nsclc

Dr Millie Das, MD discusses updates from the 2022 World Conference on Lung Cancer regarding non-small cell lung cancer (NSCLC).

Episodes

September 16th 2022EP. 1: IMpower010 Trial Evaluating Atezolizumab Versus Best Supportive Care (BSC)

Dr Millie Das, MD opens a discussion surrounding updates regarding non-small cell lung cancer (NSCLC) as presented at the 2022 World Conference on Lung Cancer (WCLC).

September 23rd 2022EP. 2: Evolving NSCLC Treatment Landscape Following IMpower010 Trial Data

IMpower010 trial data may influence a significant evolution in treatment of non–small cell lung cancer.

September 30th 2022EP. 3: Aligning Cost-Effective Payer Strategies With Clinical Pathway Considerations for NSCLC Treatment

Millie Das, MD, shares key takeaways from her presentation regarding cost-effective strategies and payer considerations related to the treatment of NSCLC.

October 7th 2022EP. 4: HUDSON Trial Overview and Key Takeaways

The HUDSON trial is explored by Dr Das as she provides an overview of the study and offers key considerations regarding results.

October 14th 2022EP. 5: JAVELIN Lung 100 Trial Evaluating Progression-Free and Overall Survival for Patients With NSCLC

Millie Das, MD, outlines the JAVELIN Lung 100 trial and shares insights on strategies and data interpretation from the trial.

October 21st 2022EP. 6: Emphasizing Biomarker-Driven Treatment and Individualized Care Strategies for Patients With NSCLC

Dr Millie Das, MD discusses updates from the 2022 World Conference on Lung Cancer regarding non-small cell lung cancer (NSCLC).

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions